ACHBT

Achieve Life Sciences is a clinical-stage pharmaceutical company focused on the development and commercialization of cytisinicline for smoking cessation and nicotine addiction. Cytisinicline is a plant-derived alkaloid that interacts with nicotinic acetylcholine receptors in the brain to reduce withdrawal symptoms and the reward associated with nicotine. The company's lead program, the ORCA (Ongoing Research in Cetisinicline for Addiction) clinical trial series, has demonstrated significant efficacy and a favorable safety profile in Phase 3 trials. Achieve aims to address the global public health crisis of tobacco use and the rising prevalence of e-cigarette addiction. The company is headquartered in Vancouver, Washington, and is advancing toward a New Drug Application (NDA) submission.